(BRK.A), (BRK.B)
Berkshire Hathaway’s Lubrizol has announced promising preclinical results highlighting the superior performance of its microencapsulated iron ingredient, Lipofer™, compared to conventional iron sources. Published in Nature, the study found that Lipofer™ microcapsules significantly improved iron absorption and gastrointestinal tolerance in iron-deficient rats—reversing iron deficiency in just 14 days.
Iron deficiency anemia (IDA) affects more than 2 billion people worldwide, particularly women. While iron supplementation is essential, common forms like ferrous sulfate often cause digestive discomfort and poor adherence due to side effects such as nausea and gut irritation.
In the in vivo study, researchers compared Lipofer™ to ferrous sulfate, ferrous bisglycinate, and other encapsulated iron salts. Key indicators such as hemoglobin levels, transferrin saturation, total iron-binding capacity (TIBC), and gut barrier integrity were measured. Lipofer™ outperformed all comparators, showing no signs of gastrointestinal irritation or inflammation, even with prolonged use.
In contrast, ferrous sulfate supplementation led to elevated IL-6 levels—a marker of inflammation—and signs of gut barrier disruption.
Lipofer™ achieves its performance through micronized, microencapsulated technology that enables targeted release in the intestine, minimizing stomach discomfort and optimizing nutrient absorption. Its formulation includes lecithin and ultra-fine iron particles, improving bioavailability while ensuring stability in various formats.
“By combining advanced formulation science with consumer-centric design, Lipofer™ microcapsules bridge the gap between efficacy and tolerability,” said Isabel Gómez, Global Marketing Manager at Lubrizol. “This study reinforces our commitment to addressing real nutritional challenges with proven performance.”
Lipofer™ is water-dispersible, stable, and highly bioavailable—making it suitable for a wide range of applications, including powder sticks, gummies, capsules, and functional foods and beverages.
These findings support Lipofer™ as a next-generation iron supplement, potentially offering a more effective and gentle alternative to traditional iron sources.
© 2025 David Mazor
Disclosure: David Mazor is a freelance writer focusing on Berkshire Hathaway. The author is long in Berkshire Hathaway, and this article is not a recommendation on whether to buy or sell the stock. The information contained in this article should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results.